Q3 Earnings Estimate for GLUE Issued By HC Wainwright

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Monte Rosa Therapeutics in a report issued on Thursday, October 1st. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.45) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Monte Rosa Therapeutics’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.81) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.54) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.22) EPS.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $8.97 million during the quarter, compared to analysts’ expectations of $12.91 million. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%.

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. dropped their price target on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Raymond James Financial set a $25.00 price objective on shares of Monte Rosa Therapeutics in a research report on Monday. Zacks Research raised shares of Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Weiss Ratings cut Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Finally, Wells Fargo & Company cut their price target on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.62.

Monte Rosa Therapeutics Price Performance

GLUE opened at $9.87 on Monday. The firm has a fifty day moving average price of $14.14 and a 200 day moving average price of $17.64. Monte Rosa Therapeutics has a 1 year low of $7.24 and a 1 year high of $25.77. The stock has a market cap of $842.04 million, a P/E ratio of -5.61 and a beta of 1.37.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Opaleye Management Inc. purchased a new position in Monte Rosa Therapeutics during the second quarter valued at $18,029,000. Squarepoint Ops LLC increased its stake in shares of Monte Rosa Therapeutics by 123.6% during the second quarter. Squarepoint Ops LLC now owns 82,953 shares of the company’s stock worth $2,007,000 after purchasing an additional 45,846 shares in the last quarter. Arizona State Retirement System acquired a new position in shares of Monte Rosa Therapeutics during the 2nd quarter worth about $321,000. HighTower Advisors LLC purchased a new position in Monte Rosa Therapeutics in the 2nd quarter valued at about $371,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Monte Rosa Therapeutics in the 2nd quarter worth about $273,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions.